EU Approves Enhertu as Adjuvant Treatment for Early HER2-Positive Breast Cancer
The EU approved Enhertu (trastuzumab deruxtecan) as adjuvant monotherapy for adults with resected HER2-positive early breast cancer and residual invasive disease after neoadjuvant treatment.
Story updates
07:30:34 AM UTC
SquawkNews
The European Commission approved Enhertu as adjuvant monotherapy for HER2 positive early breast cancer with residual invasive disease after neoadjuvant therapy. A $75M milestone is due from AstraZeneca to Daiichi Sankyo.Material DetailsContext by AI AnalystThis is a late-stage regulatory win extend…
07:36:14 AM UTC
SquawkNews
... AstraZeneca Based on DESTINY-Breast05 Phase III trial which showed AstraZeneca and Daiichi Sanky
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant…